Overview

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the combination of Nivolumab and Ramucirumab in patients with previously-treated mesothelioma.
Phase:
Phase 2
Details
Lead Sponsor:
Arkadiusz Z. Dudek, MD
Collaborators:
Bristol-Myers Squibb
Eli Lilly and Company
HealthPartners Institute Regions Cancer Care Center
Treatments:
Antibodies, Monoclonal
Nivolumab
Ramucirumab